Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you. I've been doing very well so far, when i trust my charts and stick to that. I've been good at blocking emotions too, but every once in a while, its hard not to get emotional.
I want to be 100% honest, otherwise I'll never learn and I'm here to learn and earn. I don't see how I'll be successful otherwise.
Smurf is great about that too. We're on the right target here. We just have to all help each other and support each other and knock the other down when they're a dumbass and keep each other in line.
And yes, my wife shakes her head when I tell her the dumbass moves I make too. Seems easy to her when she doesn't see the prices spiking in a moments notice (in either direction).
Good Luck to you as well... Let's learn and earn peeps.
ETRM - $2.22 - Bought 2,000 @ $2.25. They finally announced an ADCOM date after much waiting. Much selloff today on the good news, and am buying for what I hope is a near term selloff of that news today and eventual movement up in the next 2-3 days.
Yes, Thank you. I know you've been buying on any dips and been staying strong.
I bought back in today at $2.25 for 2,000 shares. Hoping this is the bottom area for today's sell off. Good Luck.
SARA - $1.14 Bought 2,000 shares @ $1.16
Sometimes I want to kick myself. I believe I'm very good at chart setup, but I have to remind myself over and over not to pinch pennies.
Case in point, SARA. I believed that it was about to make a pop. I had an order in this AM for SARA this AM for 6,000 shares @ $1.03. I could have had it for $1.04, but no.
Status Verified Canceled
Symbol SARA
Description SARATOGA RES INC TEX
Action Buy
Quantity 6,500 Shares
Route FDLM
Order Type Limit at $1.03
3 Minutes later it ran to $1.14. Emotions come into play, "hey dumbass" you missed your chart again. So, then I buy an entry at $1.16 even though it doesn't fit my chart. It still may do very well, but I need to trust the chart.
So my biggest problem to date, is trusting myself. I'll learn. Have to admit faults, to learn.
So, In SARA for a small 2,000 shares at $1.16. If it goes down to my chart "buy" I'll enter again.
Am watching ETRM and CBLI also (possible add to position).
Fantastic. That's great. It may go to $15, who knows? But just saying you have a source, without saying anything else, means nothing to me.
I was in ETRM before and have lots that I know who are in it too, I hope it goes waaay up.
Best of luck.
Ok.
Good Luck! And let us know what you learn :)
Yes, but what would be nice, is if you said "why" you think its going to blow? Back it up with chart theory, reasoning from looking at fundamentals, news that you think is coming, or a tip that your sister's friend's uncle's dogwalker gave you? List any reason.
Or, if its just a psychic feeling that you have? If someone walked into a room and says "Shit's gonna blow" and walked out and only says that? Why should we believe you?
Thanks, Give us some extra info and I'm open to any way to make a buck. Best of Luck.
Ok, good to know about Options and 401k's.
Nah, wasn't going in on this one. I stay away from events like this (after big down news).
I don't like to play them after for the most part, unless it was good news and they dip and the chart fits.
Yes, exactly. Thanks for sharing. Sorry to hear that Sheep. Its one of those times when being low on available funds helped me, as i wasn't in it.
For some reason, my 401K account only allows covered calls. Am going to call them today about that and see if I can upgrade to regular Calls/Puts.
If not, then going to put some extra $ in my other account (non -401k) which is approved for options.
I would have liked to have gotten calls only for CHTP, but won't be able to this time. I think I will be, if it goes down some still, will be buying 1 or 2k of shares to hold for approval.
16-1 approval from ADCOM. I'm not sure why it's been held down until the last couple of days, other than fear.
ETRM - ADCOM Meeting - May 29
EnteroMedics Announces Food and Drug Administration Advisory Committee Meeting Date for Review of the Maestro(R) Rechargeable System for the Treatment of Obesity
link: http://finance.yahoo.com/news/enteromedics-announces-food-drug-administration-120000694.html
Center for Devices and Radiologic Health Advisory Committee Scheduled for May 29, 2014
ST. PAUL, MN--(Marketwired - Feb 12, 2014) - EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the U.S. Food and Drug Administration's Office of Device Evaluation has scheduled a meeting of the Center for Devices and Radiologic Health's (CDRH) Advisory Committee on Thursday, May 29, 2014 to review the Maestro® System delivering VBLOC® vagal blocking therapy as a treatment for morbid obesity. The CDRH Advisory Committee is an independent panel of clinical and scientific experts that helps evaluate medical devices for safety and efficacy and makes recommendations regarding Benefit-Risk to the FDA.
more on the link... http://finance.yahoo.com/news/enteromedics-announces-food-drug-administration-120000694.html
ADCOM Meeting - May 29
EnteroMedics Announces Food and Drug Administration Advisory Committee Meeting Date for Review of the Maestro(R) Rechargeable System for the Treatment of Obesity
link: http://finance.yahoo.com/news/enteromedics-announces-food-drug-administration-120000694.html
Center for Devices and Radiologic Health Advisory Committee Scheduled for May 29, 2014
ST. PAUL, MN--(Marketwired - Feb 12, 2014) - EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the U.S. Food and Drug Administration's Office of Device Evaluation has scheduled a meeting of the Center for Devices and Radiologic Health's (CDRH) Advisory Committee on Thursday, May 29, 2014 to review the Maestro® System delivering VBLOC® vagal blocking therapy as a treatment for morbid obesity. The CDRH Advisory Committee is an independent panel of clinical and scientific experts that helps evaluate medical devices for safety and efficacy and makes recommendations regarding Benefit-Risk to the FDA.
more on the link... http://finance.yahoo.com/news/enteromedics-announces-food-drug-administration-120000694.html
XLF Hits Upper Channel - Time for Market Pause?
Just an FYI: the markets have been moving up strong last four plus days, perhaps time to keep that in mind when entering any new trades in the next few days?
Check the XLF chart from a few days ago, sitting now at $21.53, which IMO looks to be resistance from the upper channel and also from previous support / resistance levels.
Just something to think about, Trade Rationally and Carry On.
I cancelled my ACST order, only because its the end of the day and the market has been booming last few days, and can always buy it around this price tomorrow. So will wait and see what tomorrow brings.
May also buy SARA instead. I'm liking the 15 min chart and the daily too. Looks to have bottomed out.
ACST - I have an order in for 5,000 @ $1.27. See if I get it or not. I know...I'm a cheapass.
Watching... ACST, AEZS, GEVO, SARA (new one i found).
AEZS $1.28 getting interesting.
HTM - $.47 - Didn't hold the breakout around $.49. Not a lot of volume and went through my support lines for RSI and STO. All of which would have given me a signal of strength.
IMO, On the 15 min chart, looks to be heading down still.
BOL with it. Will see if it hold support at $.46ish.
Funds: At the moment any stock I enter I'd have to wait until Thursday before selling. Normally not a big deal, but in the case like IDN, I'd like to enter on a cash basis, just in case of a quick in and out was needed.
Sometime soon, when I've closed out some positions, I hope to let them all settle and then have cash for more day trades, or swing trades.
My setups are normally good for 'fast quick moves.' Those that move up fast, can move down just as fast. But hope to get them before the pop. That seems to be what I'm best at. Time will tell.
DARA: It was just one of those things, where if you listened to the CEO about KRN5500, his voice and laughter were in that "all mine, mine, mine"
then reality will set in and etc.
IGXT - I would agree to that, and also see if it drops even further to the 60's. Groovy dude.
fam401,
That's the question, yup. Is it for real?
It had 5M in volume yesterday and for what I can tell, no news yesterday except for the Seeking Alpha article last Friday (unless I missed something).
Volume has been no doubt been VERY large this past month comparatively. From looking at past spikes, you can see that each time, the move only lasted a day or three, then it came down, down, down.
But none of those had anywhere near this type of volume. So, where does it go from here?
I believe they have their earnings date in March (i have to double check that).
All this leads to, is it for real this time, or just another Pop and deflate?
And for that. I dunno. I just picked it up on one of my scans and have been watching it a week and liked that it had no debt and other things going for it.
My entries are normally great for stocks that are just about to make a move. Once they take off, its hard for me to know, when the top is the top, or if its finally for real.
So, unfortunately, its more of a wait and see for me and hard to give price levels as I use the RSI mostly.
To enter it, I'd be watching it's 15 Min chart. I use the Dailies for the overall trend and then the 15 Min chart to determine when to enter (or exit) a trade.
IMO IDN can make another move up $.10 to $.78, or go further up to $.85, $1. But she's gonna need that volume!
Volume before price. So this may be just a teaser for what's to come. I'll be watching, charting and waiting. Long assed answer for "i dunno." (too many variables).
Actually, the 15 Min chart looks good to me at the moment, assuming it has volume still coming. So, watch that. As long as the 15 Min chart (below) holds the lower RSI, then IMO, she could move up again today.
HTM
IMO: Chart does look like its about ready to make a move of some sort (hopefully up for you).
I drew some lines around what I'd be watching.
At the moment, IMO it looks to be squeezing into the descending trianglish area. A breakout above .49 on good volume, or below .45 might be telling of the direction.
I put red arrows in the indicators below. They might be showing a small curve up.
----------------------------------
Check out the weekly chart too, that might be hinting to me that it might be consolidating still. The MACD on the weekly has room before it bounces off, and hopefully doesn't cross going down.
BOL
hesse,
Re Dara: just remember...IMO dilution is coming, unless they have some type of partnership up their sleeve and their CEO kinda laughed a little bit maniacally yesterday in the presentation regarding partnership. Kinda in a "mine, she's all mine...my little pretty" way. So, dilution IMO is unfortunately coming. Hopefully it'll be after Orphan approval (if that's ever coming).
Re Magical Buses: I have finally realized that it is true. That there's NO REASON to chase any stock. Each day, from my watchlist, there's a play to be made. Somehow, in some way, things can change quickly, so just watch and wait for it to come to you and that magic bus will come and take you to HappyLand.
Re Split Decisions: Sooooooooooo true. And we all have lives to deal with. Things pulling at us when trying to make decisions; work, family, etc. So we do our best and fight to live another day.
BOL!
DARA Conference - I just listened to the archive of the webcast. If you're interested in learning more about KRN5500 (drug up for Orphan Status) kicks in around 18:00 minute mark.
webcast link : http://www.veracast.com/bio/ceoinvestor2014/main/player.cfm?eventid=72264
David Drutz CEO spoke about how well the drug treats neuropathy from Cancer and he said that FDA is still considering the Orphan Status. He did not give any specific updates, but did say that they DO NOT HAVE specific timelines in which they operate. Even though most ODD's seem to take 90days max, he mentioned that its not like it takes 30 days, or 90days. They operate at their own timeline.
Drutz also mentioned that (and of course he's going to hype it) KRN5500 is such a fantastic opportunity, that one could build an entire company JUST around the drug.
With all that said, he talked again about how they needed to do the RevSplit to maintain Nasdaq compliancy, and then will be doing financing at some point in the near future. I believe in their financials they put out recently, the mentioned that they only have enough cash for through Mar, so am expecting financing sometime soon. My guess, and its just a guess, is that they're trying to delay it as long as possible, just in case they get the Orphan approval, and would prefer to do it after that.
Am still going to hold and see what happens. May trim 1/3 still if for some reason it moves up some.
IDN $.68 - One that Got Away
I couldn't have nailed this sucker any better then what I charted out. Only problem is, I didn't enter the trade. Was one missed moment after another for various reasons (market was teetering, yada, yada), and right before I was going to enter the VERY FIRST Seeking Alpha article was written about the company, and a very impressive article at that.
It put it on everyone's radar and then momentum took over IMO and Whammo, Kablooey. Volume out the wahoo.
The good news is...there's always another bus around the corner, and...that my Wacky Chart Worked :)
Maybe...in a another 3 months? Actually, will keep it on watch to it if she spikes down. It hasn't been able to keep any gains from looking at the chart.
Added 6,000 of CBLI @ $.70
Am looking for whatever she'll give, in a short swing trade to sell tomorrow morning before their presentation (like so many are presenting today and tomorrow), or for a few days longer if need be.
It hit the 50 DMA today ($.74) and pulled back just a little as many do. Am hoping it crosses it tomorrow. Had 5x the normal volume and extended volume in AH.
--------------------
Holding RGDX : Doing well waiting on news
Holding KIPS : Waiting on volume
Holding DARA : Waiting on ..umm..err..anything
SOLD MSTX for $474 gain.
MSTX - $.84 - Sold 4000 @ $.90, sold another 3700 at .86. Profit of $464. Not exactly what I wanted out of it, but I'll take it.
They announced today that they were buying a private company Aries Pharm I think the name is, and then also an announcement of dilution as well.
A profit is a profit. Am having a lot of probs with websites today, including iHub. Connections are slow and glitchy.
IGXT - $.79 Down 7% today
CBLI - $.70 - Bought 6,000 shares at $.70
All my 3 chart indicators on the Daily point up.
Shares: +6,000.000
Price: $0.70
Amount: -$4,207.95
gonna give it a whirl. may day trade this one, or hold a bit. see how it goes.
Mast To Acquire Aires Pharmaceuticals, Inc.
- All-stock transaction
- Conference call to discuss pending acquisition today at 8:30am Eastern Time
link: http://finance.yahoo.com/news/mast-therapeutics-signs-definitive-agreement-130000447.html
(NYSE MKT: MSTX) today announced that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, Inc. (Aires), a privately-held, clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. Aires' lead product, AIR001, is an intermittently nebulized formulation of nitrite and has orphan drug status with the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of pulmonary arterial hypertension.
"The acquisition of Aires will enhance our pipeline with a phase 2 asset with more than 120 human subject exposures and which is a strategic complement to our lead program, MST-188. With total consideration of approximately 6% of Mast equity, it represents excellent value for our stockholders," stated Brian M. Culley, Chief Executive Officer of Mast Therapeutics, Inc.
"Nitrite has demonstrable beneficial properties, including vasodilation and the reduction of inflammation and undesirable cell growth. These are important therapeutic objectives and an ideal complement to MST-188 and its ability to improve blood flow and seal cellular membranes. In addition, we intend to investigate the hypothesis that AIR001 positively affects mitochondrial activity and myocyte energetics. With this acquisition, and the initiation of our phase 2 trial of MST-188 for the treatment of acute limb ischemia later this quarter, we are taking additional steps towards building a sustainable company with a valuable pipeline addressing significant unmet needs in both specialized and major markets," Mr. Culley continued.
"Another highlight of this acquisition is its favorable economics. Aires had completed several venture financings, including a $20 million Series B round. We are paying significantly less than that to acquire the program and we currently estimate that our development costs for AIR001 for the first 12 months will be approximately $2 million. Our estimated costs for AIR001 will change as we refine our development strategy over the next few months, but Aires is expected to contribute approximately $3 million of net cash at the closing of the merger, so, as currently contemplated, our first year of development of AIR001 will not require additional capital investment by Mast," Mr. Culley concluded.
Under the terms of the all-stock transaction, Aires would become a wholly-owned subsidiary of Mast Therapeutics, Inc. in exchange for shares of Mast common stock representing approximately 6% of Mast's outstanding common stock, 80% of which would be subject to a six-month holdback for certain indemnification claims of Mast. There are no milestone obligations payable to Aires. The acquisition is expected to close in February 2014, subject to customary closing conditions.
About AIR001
AIR001 (sodium nitrite) inhalation solution, also known as Aironite®, is an intermittently nebulized formulation of nitrite. Under hypoxic conditions, AIR001 is converted to nitric oxide. Nitrite mediated nitric oxide formation has several beneficial effects, including dilation of blood vessels and reduction of inflammation and undesirable cell growth.
AIR001 has been granted orphan drug status by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of pulmonary arterial hypertension.
Conference Call Information
Interested parties may access the conference call by dialing (877) 870-4263 from the U.S. and (412) 317-0790 from outside the U.S. and should request the Mast Therapeutics Corporate Update Call. The webcast will be available live via the Internet by accessing the Investors section of Mast's website at www.masttherapeutics.com/investors/. Replays of the webcast will be available on the Company's website for 30 days and a phone replay will be available through March 5, 2014 by dialing (877) 344-7529 from the U.S. and (412) 317-0088 from outside the U.S. and entering conference reference number 10040517.
MY Monday Morning Watchlist : Stocks that popped my interest over the weekend while doing research.
On Watch for possible entry:
ACHN
ACST
AEZS
CBLI
CHTP
CYTR
DRRX
GEVO
IDN
IMUC
ZLCS
BOL to all this week!
IDN - $.51 - Seeking Alpha last Friday
IMO, this is the reason for volume that came in on Friday. A very positive and impressive SA article.
Am still watching this one. IMO, SA articles sometimes have a 1-2 day staying power, so am waiting again to see if this goes down a bit back to .45-.48ish.
SA Link: http://seekingalpha.com/article/2003761-intellicheck-mobilisa-a-0_40-stock-that-should-be-trading-at-2
It's a very interesting read...
IDN is a rapidly growing company, check out the next revenue numbers:
Q4 2012: $0.53 million
Q1 2013: $1.63 million
Q2 2013: $1.72 million
Q3 2013: $2.58 million
In twelve months time, revenue rose 400%. The fact that the rollout of its technology and innovation has just begun, the fact that IDN is targeting multi-billion dollar markets, and the fact that IDN recently became, in a key segment, the first company in the world to get TSA approval, make us believe revenue is to multiply again throughout the year.
Waiting for a good price (lower) to enter or confirmation (volume) that breakout is real from here.
Thanks for this notice. I searched and found the following snippets of info from Jason's updates. Also is a link to the FULL PDF:
---------------------
DARA - $.52 - ZACK's Buy Rating - Update 2/6/14
Highlights below from the PDF...
February 6, 2014
Jason Napodano, CFA
jnapodano@zacks.com
PDF Link: http://scr.zacks.com/files/doc_coverage/Biotech%20-%20Jason%20Napodano/DARA/February%206%202014_DARA_Napodano.pdf
ODD Status: …No Update On KRN5500 ODD…
DARA’s Form 10K filed on February 4, 2014 provided little update on the status of the pending Orphan Drug Designation (ODD) decision from the U.S. FDA on KRN5500. The language from the annual report (posted below) is similar to the last update from the company in November 2013:
------------------------------
We had a brief conversation with the company for the preparation of this report. Management told us they remain in “active dialogue” with the U.S. FDA on the ODD application. This is important because many investors have asked us if the application has been rejected or moved to the back burner at either the agency of the company. This does not seem to be the case. We are hoping for a decision in the next few months.
--------------------------------
We believe DARA’s stock remains attractively valued. Revenues in 2012 were non-existent. In 2013, revenues totaled only $0.42 million, again…pretty low.
However, based on the recent sales force expansion and the three new products DARA is now co-promoting from Mission Pharmacal, we think DARA can do over $2.0 million in revenues in 2014 and $10+ million in revenues in 2016. If our modeling holds, the stock should be trading at over $5.00 by year-end 2014 (post-split), and that is based solely on the six current marketed products and has no value for KRN5500. We think orphan drug designation on KRN5500 could triple the market value of the company. A licensing partner will probably be announced soon after the FDA’s decision. Our conclusion is that investors can buy DARA now and get both an emerging specialty pharmaceutical story at a reasonable price, and a Phase 2b drug in KRN5500 for free.
Current Recommendation Buy
Prior Recommendation Neutral
Date of Last Change 09/13/2012
Current Price (02/06/14) $0.52
Target Price $1.50
Ok. Thank you.
DARA - 50DMA Hits the 200DMA. It didn't cross it, but is exactly the same price $.599. Let's hope it crosses and doesn't bounce off. Looking at the chart, man it fell a long way. Let's hope rubberband theory comes into play, bounces back and not breaks.
skichic, What update are you looking for? I just picked this up on radar a few days ago and have been looking into it. I wasn't sure when Earnings are being reported either.
I read up some about their deal with Coke in the past and also with Richard Branson owning some of it and then their delay of the Minnesota Facility, but need to read more. Kinda liking the chart, so watching.
Smurf, And how was your Friday?
XLF : Financial ETF - Strong move into the next channel today. It started out good, then moved back down to yesterday's close (21.05) - (old resistance / new support) and said that NORTH is the way to go. Decent enough volume.
Also - jobs report. Sentiment was the key again to me, as the report was worse than what peeps wanted. So it dropped down in futures, then came right back up before market open, and then basically... IMO the market said "So what? - We want to go higher - so who cares what it says." Makes a Happy Friday
I'll take days like these whenever they want to give them. up 6.5% - green on all 4 (kips, dara, mstx, rgdx). $1,500 gain today, so down only $1,500 (mostly all dara).
Hoping for a halfway decent market week next week.